Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Next Previous
Trial Profile

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSENT
  • Sponsors Altamira Therapeutics

    • Most Recent Events

    • 18 Apr 2018 Status changed from active, no longer recruiting to discontinued.
    • 04 Jan 2018 According to an Auris Medical media release, the company plans to discuss the accumulated safety and efficacy data from the trial and the regulatory pathway with the FDA and EMA in the second quarter of 2018.
    • 04 Jan 2018 According to an Auris Medical media release, the company expects data from a further 31 patients towards the end of the first quarter of 2018. The data will also be submitted for peer review publication and presentation at a medical meeting in 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top